Liraglutide and Insulin Therapy in Patients With Type 2 Diabetes

What this study is testing ClinicalTrials.gov NCT01392898 ↗

Description as written by the study sponsor.

Insulin therapy is frequently needed to achieve adequate glycaemic control in type 2 diabetes. Although insulin is an effective treatment modality, this is often at the expense of significant weight gain. Weight gain is obviously undesirable in an already overweight population, but may also deter further optimization of insulin therapy. Large inter-individual differences exist in the level of weight gain after initiation of insulin therapy, but no clear predictive factors have prospectively been identified thus far. Liraglutide (Victoza®), a human glucagon-like peptide-1 (GLP-1) analogue, improves glycaemic control and reduces weight. We hypothesize that in patients who show (excessive) weight gain after introducing insulin therapy, adding liraglutide is effective in reversing body weight while preserving glycaemic control.

Treatments tested

• liraglutide Drug

  liraglutide 1.8 mg q.d.

• Insulin Drug

  insulin dosed according titration scheme